X-linked hypophosphataemia (XLH)

Progressive, chronic, skeletal1,2

XLH is characterised by renal phosphate wasting, which is caused by excess fibroblast growth factor 23 (FGF23) production1,2

Pediatric skeletal manifestations and  Adult skeletal manifestation Pediatric skeletal manifestations andAdult skeletal manifestation

See the lifelong spectrum of XLH

Round image with gene representation

Discover how FGF23 impacts phosphate homeostasis

Watch the video
Pyramid image with Skeletal/Biochemical/Physical Function sections

Help improve outcomes through early assessment

1. Martin A, Quarles LD. Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis. Adv Exp Med Biol. 2012;728:65-83. 2. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381-1388. 3. Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3(1):R13-R30. 4. Zivičnjak M, Schnabel D, Billing H, et al. Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr Nephrol. 2011;26(2):223-231. 5. Che H, Roux C, Etcheto A, et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol. 2016;174(3):325-333. 6. Skrinar A, Dvorak-Ewell M, Evins A, et al. The lifelong impact of X-linked hypophosphataemia: results from a burden of disease survey. J Endocr Soc. 2019;3(7):1321-1334. 7. Veilleux LN, Cheung M, Ben Amor M, Rauch F. Abnormalities in muscle density and muscle function in hypophosphatemic rickets. J Clin Endocrinol Metab. 2012;97(8):E1492-E1498. 8. Looser zones. Radiopaedia Web site. https://radiopaedia.org/articles/looser-zones-1. Accessed October 9, 2017. 9. Theodore-Oklota C, Bonner N, Spencer H et al. Qualitative research to explore the patient experience of X-linked hypophosphataemia and evaluate the suitability of the BPI-SF and WOMAC® as clinical trial end points. Value Health. 2018;21(8):973-983.

XLH Link

You are about to leave a Kyowa Kirin website

You are leaving the XLH Link website to a site that is not under the control of Kyowa Kirin. Kyowa Kirin is not responsible for the content of any such site or any further link from such site. Are you sure you want to continue?

Welcome to
XLH Link

This website is designed specifically for HCPs to provide information about X-LinkedHypophosphataemia (XLH).

To continue to the website please select your country

Spain

Germany

Portugal

If your country is not listed please go to the European page below